Abstract

Background:Preclinical rodent models for Parkinson’s disease (PD) based on viral human alpha-synuclein (h-αSyn) overexpression recapitulate some of the pathological hallmarks as it presents in humans, such as progressive cell loss and additional synucleinopathy in cortical and subcortical structures. Recent studies have combined viral vector-based overexpression of human wild-type αSyn with the sequential or simultaneous inoculation of preformed fibrils (PFFs) derived from human αSyn.Objective:The goal of the study was to investigate whether sequential or combined delivery of the AAV vector and the PFFs are equipotent in inducing stable neurodegeneration and behavioral deficits.Methods:Here we compare between four experimental paradigms (PFFs only, AAV-h-αSyn only, AAV-h-αSyn with simultaneous PFFs, and AAV-h-αSyn with sequential PFFs) and their respective GFP control groups.Results:We observed reduction of TH expression and loss of neurons in the midbrain in all AAV (h-αSyn or GFP) injected groups, with or without additional PFFs inoculation. The overexpression of either h-αSyn or GFP alone induced motor deficits and dysfunctional dopamine release/reuptake in electrochemical recordings in the ipsilateral striatum. However, we observed a substantial formation of insoluble h-αSyn aggregates and inflammatory response only when h-αSyn and PFFs were combined. Moreover, the presence of h-αSyn induced higher axonal pathology compared to control groups.Conclusion:Simultaneous AAV and PFFs injections are equipotent in the presented experimental setup in inducing histopathological and behavioral changes. This model provides new and interesting possibilities for characterizing PD pathology in preclinical models and means to assess future therapeutic interventions.

Highlights

  • The most common preclinical rodent models of Parkinson’s disease (PD) are produced by either injecting neurotoxicants, overexpressing PDrelated genes, or by introducing mutations

  • All groups injected with associated viral (AAV)-human alpha-synuclein (h-␣Syn) displayed a similar degree of ␣Syn immunoreactivity which was absent in the group that received preformed fibrils (PFFs) only (Sidak, all p < 0.0001)

  • We report pSer129+, Ub+, and ThioS+ inclusions in surviving midbrain neurons in all the groups injected with AAV-h-␣Syn and/or PFFs implying the development of Lewy-like pathology

Read more

Summary

Introduction

The most common preclinical rodent models of Parkinson’s disease (PD) are produced by either injecting neurotoxicants, overexpressing PDrelated genes, or by introducing mutations Neurotoxicants such as 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) cause a robust and rapid degeneration of the dopaminergic midbrain system, with subsequent behavioral impairments [1–6]. There is a great heterogeneity in the results from AAV-based studies in terms of ␣Syn expression levels, neurodegeneration, and behavioral deficits. Recent studies have combined viral vector-based overexpression of human wild-type ␣Syn with the sequential or simultaneous inoculation of preformed fibrils (PFFs) derived from human ␣Syn. Objective: The goal of the study was to investigate whether sequential or combined delivery of the AAV vector and the PFFs are equipotent in inducing stable neurodegeneration and behavioral deficits. The presence of h-␣Syn induced higher axonal pathology compared to control groups

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call